|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu XF, Li W, Ma JY, Shao N, Zhang YJ, Liu
RM, Wu WB, Lin Y and Wang SM: Knockdown of heme oxygenase-1
promotes apoptosis and autophagy and enhances the cytotoxicity of
doxorubicin in breast cancer cells. Oncol Lett. 10:2974–2980.
2015.
|
|
4
|
Zheng Y, Lv X, Wang X, Wang B, Shao X,
Huang Y, Shi L, Chen Z, Huang J and Huang P: MiR-181b promotes
chemoresistance in breast cancer by regulating Bim expression.
Oncol Rep. 35:683–690. 2016.
|
|
5
|
Faneyte IF, Kristel PM, Maliepaard M,
Scheffer GL, Scheper RJ, Schellens JH and van de Vijver MJ:
Expression of the breast cancer resistance protein in breast
cancer. Clin Cancer Res. 8:1068–1074. 2002.PubMed/NCBI
|
|
6
|
Jeon YJ, Kim JH, Shin JI, Jeong M, Cho J
and Lee K: Salubrinal-mediated upregulation of eIF2α
phosphorylation increases doxorubicin sensitivity in MCF-7/ADR
cells. Mol Cells. 39:129–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perrotti D and Neviani P: Protein
phosphatase 2A: A target for anticancer therapy. Lancet Oncol.
14:e229–e238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Alaaho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seshacharyulu P, Pandey P, Datta K and
Batra SK: Phosphatase: PP2A structural importance, regulation and
its aberrant expression in cancer. Cancer Lett. 335:9–18. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schönthal AH: Role of serine/threonine
protein phosphatase 2A in cancer. Cancer Lett. 170:1–13. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lv P, Wang Y, Ma J, Wang Z, Li JL, Hong
CS, Zhuang Z and Zeng YX: Inhibition of protein phosphatase 2A with
a small molecule LB100 radiosensitizes nasopharyngeal carcinoma
xenografts by inducing mitotic catastrophe and blocking DNA damage
repair. Oncotarget. 5:7512–7524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia
J and Xu D: CIP2A is overexpressed in gastric cancer and its
depletion leads to impaired clonogenicity, senescence, or
differentiation of tumor cells. Clin Cancer Res. 14:3722–3728.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W,
Liu J and Zhou GB: Cancerous inhibitor of PP2A is targeted by
natural compound celastrol for degradation in non-small-cell lung
cancer. Carcinogenesis. 35:905–914. 2014. View Article : Google Scholar
|
|
14
|
Ren J, Li W, Yan L, Jiao W, Tian S, Li D,
Tang Y, Gu G, Liu H and Xu Z: Expression of CIP2A in renal cell
carcinomas correlates with tumour invasion, metastasis and
patients' survival. Br J Cancer. 105:1905–1911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu CY, Shiau CW, Kuo HY, Huang HP, Chen
MH, Tzeng CH and Chen KF: Cancerous inhibitor of protein
phosphatase 2A determines bortezomib-induced apoptosis in leukemia
cells. Haematologica. 98:729–738. 2013. View Article : Google Scholar :
|
|
16
|
Choi YA, Park JS, Park MY, Oh KS, Lee MS,
Lim JS, Kim KI, Kim KY, Kwon J, Yoon Y, et al: Increase in CIP2A
expression is associated with doxorubicin resistance. FEBS Lett.
585:755–760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Wang M, Zhang X, Wang Q, Qi M, Hu
J, Zhou Z, Zhang C, Zhang W, Zhao W, et al: CIP2A is associated
with multidrug resistance in cervical adenocarcinoma by a
P-glycoprotein pathway. Tumour Biol. 7:2673–2682. 2015.
|
|
18
|
Lai GM, Ozols RF, Young RC and Hamilton
TC: Effect of glutathione on DNA repair in cisplatin-resistant
human ovarian cancer cell lines. J Natl Cancer Inst. 81:535–539.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
El-Senduny FF, Badria FA, El-Waseef AM,
Chauhan SC and Halaweish F: Approach for chemosensitization of
cisplatin-resistant ovarian cancer by cucurbitacin B. Tumour Biol.
37:685–698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To
Y, Lee WH, Li M, Chu KH and Toh M: Cucurbitacin B induces apoptosis
and S phase cell cycle arrest in BEL-7402 human hepatocellular
carcinoma cells and is effective via oral administration. Cancer
Lett. 294:118–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan KT, Li K, Liu SL, Chu KH, Toh M and
Xie WD: Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway
in leukemia cell line K562. Cancer Lett. 289:46–52. 2010.
View Article : Google Scholar
|
|
22
|
Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu
YP, Yu XJ, Zhang XD, Ming PH, Zhou GB, et al: The natural compound
magnolol inhibits invasion and exhibits potential in human breast
cancer therapy. Sci Rep. 3:30982013.PubMed/NCBI
|
|
23
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P, et al: Homoharringtonine
induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal
pathway in Gefitinib-resistant lung cancer cells. Sci Rep.
5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chou CC, Yang JS, Lu HF, Ip SW, Lo C, Wu
CC, Lin JP, Tang NY, Chung JG, Chou MJ, et al: Quercetin-mediated
cell cycle arrest and apoptosis involving activation of a caspase
cascade through the mitochondrial pathway in human breast cancer
MCF-7 cells. Arch Pharm Res. 33:1181–1191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Dong Y, Zhang B and Cheng YX: Small
compound 6-O-angeloylplenolin induces caspase-dependent apoptosis
in human multiple myeloma cells. Oncol Lett. 6:556–558.
2013.PubMed/NCBI
|
|
26
|
Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang
Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET
oncoprotein is associated with tumor progression and poor prognosis
in human non-small cell lung cancer. Oncotarget. 6:14913–14925.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Radisavljevic Z: AKT as locus of cancer
multidrug resistance and fragility. J Cell Physiol. 228:671–674.
2013. View Article : Google Scholar
|
|
28
|
Rincón R, Cristóbal I, Zazo S, Arpí O,
Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, et
al: PP2A inhibition determines poor outcome and doxorubicin
resistance in early breast cancer and its activation shows
promising therapeutic effects. Oncotarget. 6:4299–4314. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo J, Zhao W, Hao W, Ren G, Lu J and Chen
X: Cucurbitacin B induces DNA damage, G2/M phase arrest, and
apoptosis mediated by reactive oxygen species (ROS) in leukemia
K562 cells. Anticancer Agents Med Chem. 14:1146–1153. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marsden VS, O'Connor L, O'Reilly LA, Silke
J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ,
et al: Apoptosis initiated by Bcl-2-regulated caspase activation
independently of the cytochrome c/Apaf-1/caspase-9 apoptosome.
Nature. 419:634–637. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nicholson DW: Caspase structure,
proteolytic substrates, and function during apoptotic cell death.
Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alcantara LM, Kim J, Moraes CB, Franco CH,
Franzoi KD, Lee S, Freitas-Junior LH and Ayong LS:
Chemosensitization potential of P-glycoprotein inhibitors in
malaria parasites. Exp Parasitol. 134:235–243. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Luo L, Sun YJ, Yang L, Huang S and Wu YJ:
Avermectin induces P-glycoprotein expression in S2 cells via the
calcium/calmodulin/NF-κB pathway. Chem Biol Interact. 203:430–439.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ying L, Zu-An Z, Qing-Hua L, Qing-Yan K,
Lei L, Tao C and Yong-Ping W: RAD001 can reverse drug resistance of
SGC7901/DDP cells. Tumour Biol. 35:9171–9177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cristóbal I, Rincón R, Manso R, Caramés C,
Zazo S, Madoz-Gúrpide J, Rojo F and García-Foncillas J:
Deregulation of the PP2A inhibitor SET shows promising therapeutic
implications and determines poor clinical outcome in patients with
metastatic colorectal cancer. Clin Cancer Res. 21:347–356. 2015.
View Article : Google Scholar
|
|
39
|
Yu HC, Hung MH, Chen YL, Chu PY, Wang CY,
Chao TT, Liu CY, Shiau CW and Chen KF: Erlotinib derivative
inhibits hepatocellular carcinoma by targeting CIP2A to reactivate
protein phosphatase 2A. Cell Death Dis. 5:e13592014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Côme C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
